Paragonix Technologies has announced the completion of the world’s first-in-human use of the BAROguard Donor Lung Preservation System by Duke University Medical Center in the US.

Earlier this year, the company received 510(k) clearance from the US Food and Drug Administration for this system.

Conducted by Dr Kunal Patel, the groundbreaking case safely protected a pair of donor lungs travelling over 600 miles.

The BAROguard system kept the donor lungs safe and monitored them for more than six hours during their transportation for a life-saving transplant.

It is claimed to be the first commercially available hypothermic preservation system that can control the airway pressure of donor lungs automatically when outside the body at the time of preservation and transportation.

The new technology helps maintain the optimal temperature range and adhere to the clinically recommended inflation pressure range, thereby helping to eliminate the traditional risks that occur during transport.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The transmission of temperature and airway pressure data to transplant teams in real time enables full visibility into the lung’s conditions during transport.

Paragonix CEO and president Lisa Anderson said: “This exciting milestone serves as a testament to the BAROguard System’s potential to revolutionise lung preservation and transport.

“We will continue to push the boundaries of innovation to provide more advanced tools for healthcare professionals and better outcomes for patients.”